Triple Negative Breast Neoplasms

"Triple Negative Breast Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.

Descriptor ID	D064726
MeSH Number(s)	C04.588.180.788 C17.800.090.500.788
Concept/Terms	Triple Negative Breast Neoplasms Triple Negative Breast Neoplasms ER-Negative PR-Negative HER2-Negative Breast Neoplasms ER Negative PR Negative HER2 Negative Breast Neoplasms Triple-Negative Breast Cancer Breast Cancer, Triple-Negative Breast Cancers, Triple-Negative Triple-Negative Breast Cancers Triple-Negative Breast Neoplasm Breast Neoplasm, Triple-Negative Breast Neoplasms, Triple-Negative Triple Negative Breast Neoplasm Triple-Negative Breast Neoplasms ER-Negative PR-Negative HER2-Negative Breast Cancer ER Negative PR Negative HER2 Negative Breast Cancer Triple Negative Breast Cancer

Below are MeSH descriptors whose meaning is more general than "Triple Negative Breast Neoplasms".

Diseases [C]
Neoplasms [C04]
Neoplasms by Site [C04.588]
Breast Neoplasms [C04.588.180]
Triple Negative Breast Neoplasms [C04.588.180.788]
Skin and Connective Tissue Diseases [C17]
Skin Diseases [C17.800]
Breast Diseases [C17.800.090]
Breast Neoplasms [C17.800.090.500]
Triple Negative Breast Neoplasms [C17.800.090.500.788]

Below are MeSH descriptors whose meaning is related to "Triple Negative Breast Neoplasms".

Below are MeSH descriptors whose meaning is more specific than "Triple Negative Breast Neoplasms".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Triple Negative Breast Neoplasms" by people in this website by year, and whether "Triple Negative Breast Neoplasms" was a major or minor topic of these publications.

Bar chart showing 26 publications over 10 distinct years, with a maximum of 5 publications in 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2013	0	1	1
2014	2	0	2
2015	3	0	3
2016	2	1	3
2017	2	0	2
2018	2	1	3
2019	5	0	5
2020	2	0	2
2021	2	1	3
2022	2	0	2

Below are the most recent publications written about "Triple Negative Breast Neoplasms" by people in Profiles.

Carrillo P, Bernal M, T?llez-Quijorna C, Marrero AD, Vidal I, Castilla L, Caro C, Dom?nguez A, Garc?a-Mart?n ML, Quesada AR, Medina MA, Mart?nez-Poveda B. The synthetic molecule stauprimide impairs cell growth and migration in triple-negative breast cancer. Biomed Pharmacother. 2023 Feb; 158:114070.

View in: PubMed
Murthy SRK, Cheng X, Zhuang T, Ly L, Jones O, Basadonna G, Keidar M, Canady J. BCL2A1 regulates Canady Helios Cold Plasma-induced cell death in triple-negative breast cancer. Sci Rep. 2022 03 08; 12(1):4038.

View in: PubMed
Paes Dias M, Tripathi V, van der Heijden I, Cong K, Manolika EM, Bhin J, Gogola E, Galanos P, Annunziato S, Lieftink C, And?jar-S?nchez M, Chakrabarty S, Smith GCM, van de Ven M, Beijersbergen RL, Bartkova J, Rottenberg S, Cantor S, Bartek J, Ray Chaudhuri A, Jonkers J. Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps. Mol Cell. 2021 11 18; 81(22):4692-4708.e9.

View in: PubMed
Schwartz AD, Adusei A, Tsegaye S, Moskaluk CA, Schneider SS, Platt MO, Seifu D, Peyton SR, Babbitt CC. Genetic Mutations Associated with Hormone-Positive Breast Cancer in a Small Cohort of Ethiopian Women. Ann Biomed Eng. 2021 Aug; 49(8):1900-1908.

View in: PubMed
Huna A, Nawrocki-Raby B, Padilla-Benavides T, Gavard J, Coscoy S, Bernard D, Boissan M. Loss of the Metastasis Suppressor NME1, But Not of Its Highly Related Isoform NME2, Induces a Hybrid Epithelial-Mesenchymal State in Cancer Cells. Int J Mol Sci. 2021 Apr 02; 22(7).

View in: PubMed
Cruz-Gordillo P, Honeywell ME, Harper NW, Leete T, Lee MJ. ELP-dependent expression of MCL1 promotes resistance to EGFR inhibition in triple-negative breast cancer cells. Sci Signal. 2020 11 17; 13(658).

View in: PubMed
Medina MA, Oza G, Sharma A, Arriaga LG, Hern?ndez Hern?ndez JM, Rotello VM, Ramirez JT. Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies. Int J Environ Res Public Health. 2020 03 20; 17(6).

View in: PubMed
Bolf EL, Gillis NE, Barnum MS, Beaudet CM, Yu GY, Tomczak JA, Stein JL, Lian JB, Stein GS, Carr FE. The Thyroid Hormone Receptor-RUNX2 Axis: A Novel Tumor Suppressive Pathway in Breast Cancer. Horm Cancer. 2020 02; 11(1):34-41.

View in: PubMed
Nama S, Muhuri M, Di Pascale F, Quah S, Aswad L, Fullwood M, Sampath P. MicroRNA-138 is a Prognostic Biomarker for Triple-Negative Breast Cancer and Promotes Tumorigenesis via TUSC2 repression. Sci Rep. 2019 09 03; 9(1):12718.

View in: PubMed
Heijink AM, Everts M, Honeywell ME, Richards R, Kok YP, de Vries EGE, Lee MJ, van Vugt MATM. Modeling of Cisplatin-Induced Signaling Dynamics in Triple-Negative Breast Cancer Cells Reveals Mediators of Sensitivity. Cell Rep. 2019 08 27; 28(9):2345-2357.e5.

View in: PubMed

People

Explore

Similar Concepts

Top Journals